Trade Cyclerion Therapeutics, Inc. - CYCN CFD

Add to favourite

2.5928

6.34%

View detailed chart

To be able to trade stocks like this, create an account and apply for a stock listing.

Create Account

Summary
Historical Data

Trading сonditions

Spread

0.1444

Long position overnight fee

-0.023679%

Short position overnight fee

0.001457%

Overnight fee time

21:00 (UTC)

Min traded quantity

0.01

Currency

USD

Margin

5.00%

Stock exchange

United States of America

Commission on trade

Key Stats

Prev. Close	2.5228
Open	2.4928
1-Year Change	-18.31%
Day's Range	2.4828 - 2.6928

Last Week
Last Month
Last Year
Last two Years
Max

Daily
Weekly
Monthly

Date	Close	Change	Change (%)	Open	High	Low
Apr 1, 2025	2.5228	0.0300	1.20%	2.4928	2.5828	2.4928
Mar 31, 2025	2.4128	-0.0600	-2.43%	2.4728	2.4928	2.3928
Mar 28, 2025	2.4928	-0.0100	-0.40%	2.5028	2.5128	2.4228
Mar 27, 2025	2.5028	0.0000	0.00%	2.5028	2.5128	2.4328
Mar 26, 2025	2.5128	-0.0900	-3.46%	2.6028	2.6828	2.4628
Mar 25, 2025	2.6928	-0.1000	-3.58%	2.7928	2.8428	2.6328
Mar 24, 2025	2.8128	0.1400	5.24%	2.6728	2.8228	2.6728
Mar 21, 2025	2.6728	-0.0200	-0.74%	2.6928	2.7428	2.6728
Mar 20, 2025	2.7028	0.2100	8.42%	2.4928	2.7528	2.4928
Mar 19, 2025	2.5328	-0.0400	-1.55%	2.5728	2.6228	2.5328
Mar 18, 2025	2.5728	0.1000	4.04%	2.4728	2.6828	2.4528
Mar 17, 2025	2.5428	0.0800	3.25%	2.4628	2.5828	2.4328
Mar 14, 2025	2.4928	0.0300	1.22%	2.4628	2.5528	2.4628
Mar 13, 2025	2.4628	-0.0300	-1.20%	2.4928	2.5028	2.4128
Mar 12, 2025	2.5428	0.0500	2.01%	2.4928	2.6128	2.4628
Mar 11, 2025	2.5328	-0.0900	-3.43%	2.6228	2.6828	2.5028
Mar 10, 2025	2.5728	-0.2200	-7.88%	2.7928	2.8128	2.4928
Mar 7, 2025	2.7928	0.2200	8.55%	2.5728	2.8528	2.5228
Mar 6, 2025	2.5928	0.1900	7.91%	2.4028	2.7528	2.3228
Mar 5, 2025	2.4128	-0.1800	-6.94%	2.5928	2.5928	2.2728

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission

1:1
2:1
3:1
5:1
10:1
20:1

Leverage

20:1

20
100
500
1000
10000

Investment

Trade size (Leverage x Investement):

Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Cyclerion Therapeutics, Inc. Company profile

About Cyclerion Therapeutics Inc

Cyclerion Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company's lead asset, CY6463, is a central nervous system (CNS)-penetrant, soluble guanylate cyclase (sGC) stimulator that is in clinical development for Alzheimer's disease with vascular pathology (ADv), cognitive impairment associated with schizophrenia (CIAS), and mitochondrial encephalomyopathy, lactic acidosis and stroke-like episodes (MELAS). CY6463 is an orally administered CNS-penetrant sGC stimulator that is being developed as a symptomatic and disease-modifying therapy for serious CNS diseases. Its CNS asset, CY3018, is a differentiated CNS-penetrant sGC stimulator with CSF-to-plasma exposure relative to CY6463. CY3018 is focused on sGC stimulation for the treatment of disorders of the CNS. Its non-CNS assets include Praliciguat and Olinciguat. Praliciguat is an orally administered, once-daily systemic sGC stimulator. Olinciguat is an orally administered, once-daily, vascular sGC stimulator.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Cyclerion Therapeutics Inc revenues increased 72% to $3.9M. Net loss decreased 34% to $51.6M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Research & Development - Balancing value decrease of 32% to $33.7M (expense), General & Administrative - Balancing decrease of 27% to $15M (expense).

Industry:

Biotechnology & Medical Research (NEC)

301 Binney Street
CAMBRIDGE
MASSACHUSETTS 02142
US